Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce alpha-synuclein phosphorylation in rat brain.
Aubele, D.L., Hom, R.K., Adler, M., Galemmo, R.A., Bowers, S., Truong, A.P., Pan, H., Beroza, P., Neitz, R.J., Yao, N., Lin, M., Tonn, G., Zhang, H., Bova, M.P., Ren, Z., Tam, D., Ruslim, L., Baker, J., Diep, L., Fitzgerald, K., Hoffman, J., Motter, R., Fauss, D., Tanaka, P., Dappen, M., Jagodzinski, J., Chan, W., Konradi, A.W., Latimer, L., Zhu, Y.L., Sham, H.L., Anderson, J.P., Bergeron, M., Artis, D.R.(2013) ChemMedChem 8: 1295-1313
- PubMed: 23794260 
- DOI: 10.1002/cmdc.201300166
- Primary Citation of Related Structures:  
4I5P, 4I5M, 4I6B, 4I6F, 4I6H - PubMed Abstract: 
Polo-like kinase-2 (Plk-2) has been implicated as the dominant kinase involved in the phosphorylation of α-synuclein in Lewy bodies, which are one of the hallmarks of Parkinson's disease neuropathology. Potent, selective, brain-penetrant inhibitors o ...